Core Viewpoint - A class action securities lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged securities fraud affecting investors between August 3, 2023, and December 26, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx made misleading statements regarding the efficacy of setrusumab, particularly that while it increases bone density, it does not correlate with a decrease in annualized fracture rates [2] - On December 29, 2025, Ultragenyx announced that its Phase III Orbit and Cosmic Studies did not achieve statistical significance in reducing annualized clinical fracture rates compared to placebo or bisphosphonates [2] - Following this announcement, Ultragenyx's stock price plummeted from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025, marking a decline of approximately 42.32% in one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until April 6, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Insights - Ultragenyx Pharmaceutical Inc. reported total revenue of $673 million for the year ended December 31, 2025, representing a 20% increase compared to the previous year [5][4] - The company has initiated a strategic restructuring plan aimed at reducing operating expenses and headcount, with a goal of achieving profitability by 2027 [9][10] - Key catalysts for 2026 include two potential product approvals and pivotal Phase 3 data from the GTX-102 study for Angelman syndrome [1][11] Financial Performance - In Q4 2025, total revenue was $207 million, a 25% increase from Q4 2024 [4][6] - Crysvita revenue for 2025 was $481 million, up 17% year-over-year, with significant growth in Latin America and Türkiye [5][6] - Dojolvi revenue for 2025 reached $96 million, reflecting a 9% increase compared to the prior year [5][6] Operating Expenses - Total operating expenses for Q4 2025 were $321 million, and for the full year, they amounted to $1.2 billion [7][6] - The company incurred a net loss of $129 million in Q4 2025, slightly improved from a net loss of $133 million in Q4 2024 [8][6] - For the year, the net loss was $575 million, compared to a net loss of $569 million in 2024 [8][6] Strategic Restructuring - The strategic restructuring plan includes a 10% workforce reduction, impacting approximately 130 employees [10] - Revenue guidance for 2026 is projected to be between $730 million and $760 million, indicating an 8% to 13% increase compared to 2025 [10] - The plan aims to align resources with high-impact opportunities and reduce costs to support future growth [9][10] Clinical and Regulatory Developments - The company expects pivotal data from the GTX-102 Phase 3 Aspire study in the second half of 2026 [11] - Anticipated regulatory actions include a PDUFA date for DTX401 in Q3 2026 and ongoing developments for UX111 and UX701 [15][11]

Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (RARE) for alleged material misstatements and omissions regarding its drug setrusumab, affecting investors who purchased stock between August 3, 2023, and December 26, 2025 [1] Summary by Relevant Sections Lawsuit Details - The lawsuit is filed in the United States District Court for the Northern District of California, under the case name Bailey v. Ultragenyx Pharmaceutical Inc., Case No. 3:26-cv-01097 (N.D. Cal.) [1] - Investors have until April 6, 2026, to file for lead plaintiff status [1] Allegations - The complaint alleges that Ultragenyx misrepresented the reliability of information regarding the effects of setrusumab on patients with Osteogenesis Imperfecta, downplaying the risks associated with the Phase III Orbit study [1] - It is claimed that Ultragenyx's optimism regarding the study results was unfounded, as the Phase II results lacked a placebo control group, raising concerns about the validity of the reported reduction in annualized fracture rate (AFR) [1] - The lawsuit asserts that the positive statements made by Ultragenyx about its business and prospects were materially misleading and lacked a reasonable basis [1] Investor Actions - Investors are advised to retain counsel or contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation [1] - The process for becoming a lead plaintiff is outlined, emphasizing that the lead plaintiff represents the interests of all class members [1]

Core Viewpoint - A class action lawsuit has been initiated against Ultragenyx Pharmaceutical, Inc. for allegedly misleading investors regarding the efficacy of its drug setrusumab during the Class Period from August 3, 2023, to December 26, 2025 [1]. Group 1: Legal Action - Investors have until April 6, 2026, to file a lead plaintiff motion in the class action lawsuit [1]. - The Portnoy Law Firm is encouraging affected investors to contact them for legal rights discussions and case evaluations [2]. Group 2: Allegations Against Ultragenyx - The complaint claims that Ultragenyx misrepresented the reliability of information regarding setrusumab's effects on Osteogenesis Imperfecta patients and downplayed the risks of failure in the Phase III Orbit study [3]. - It is alleged that Ultragenyx's optimism regarding the Phase III Orbit study was unfounded, as the results were based on Phase II data without a placebo control group, potentially leading to misleading conclusions about the drug's effectiveness [3]. - The lawsuit asserts that the positive statements made by Ultragenyx about its business and prospects were materially misleading and lacked a reasonable basis [3].

Corporate Presentation February 2026 Confidential and Proprietary Forward looking statements Cautionary note regarding forward-looking statements: This presentation contains forward-looking statements, including, but not limited to, statements regarding our expectations, estimates, assumptions, and projections regarding our future operating results and financial performance, including our expectations for profitability in 2027, anticipated cost or expense management, including the company's expectations rel ...

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for securities fraud, alleging that the company misled investors regarding the efficacy of its drug setrusumab in clinical trials [1] Group 1: Lawsuit Details - The lawsuit covers purchasers of Ultragenyx common stock from August 3, 2023, to December 26, 2025, and claims that the company provided misleading information about the expected results of its Phase III Orbit and Cosmic Studies [1] - Defendants allegedly made positive statements about setrusumab's ability to reduce annualized fracture rates in Osteogenesis Imperfecta patients while concealing material adverse facts about the drug's true potential [1] - The lawsuit asserts that these misleading statements led to Ultragenyx securities being purchased at artificially inflated prices, resulting in investor damages when the truth was revealed [1] Group 2: Legal Representation - Investors wishing to join the class action can do so without any out-of-pocket fees through a contingency fee arrangement [1] - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and encourages selecting qualified counsel with a proven track record [1] - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 alone [1]

Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly making false and misleading statements regarding its drug setrusumab during the class period from August 3, 2023, to December 26, 2025 [2][5]. Summary by Relevant Sections Lawsuit Details - The lawsuit is filed in the United States District Court for the Northern District of California, under the case name Bailey v. Ultragenyx Pharmaceutical Inc., et al, Case No. 3:26-cv-01097 [2]. - Investors have until April 6, 2026, to file for lead plaintiff status [2][5]. Allegations - The complaint alleges that Ultragenyx misrepresented its knowledge about the effects of setrusumab on patients with Osteogenesis Imperfecta and downplayed the risks associated with the Phase III Orbit study [3]. - It is claimed that Ultragenyx's optimism regarding the study results was unfounded, as the Phase II results lacked a placebo control group, raising concerns about the validity of the reported reduction in annualized fracture rate (AFR) [3]. - The lawsuit asserts that the positive statements made by the company regarding its business and prospects were materially misleading [3]. Investor Actions - Investors affected by the alleged fraud are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options at no cost [5][6]. - The lead plaintiff process allows investors to seek representation in the lawsuit, with the deadline set for April 6, 2026 [4][6]. Law Firm Information - Kessler Topaz Meltzer & Check, LLP is a prominent law firm specializing in securities-fraud class actions and has a history of significant recoveries in securities litigation [8].

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Viewpoint - Ultragenyx Pharmaceutical Inc is facing a federal securities class action due to allegations of making false or misleading statements regarding the efficacy of its drug setrusumab for Osteogenesis Imperfecta, leading to significant stock price declines following study failures [1][2] Summary by Relevant Sections Company Overview - Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) is under investigation by Faruqi & Faruqi, LLP for potential securities law violations related to its clinical trials [1] Allegations - The complaint alleges that Ultragenyx and its executives misrepresented the reliability of information regarding setrusumab's effects and downplayed risks associated with the Phase III Orbit study [1] - It is claimed that Ultragenyx failed to disclose that the Phase II results lacked a placebo control group, which could have influenced the perceived efficacy of the treatment [1] Stock Performance - Following the announcement on July 9, 2025, that the Phase III Orbit study did not achieve statistical significance, Ultragenyx's stock price fell by over 25% [1] - On December 29, 2025, after revealing that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, the stock price dropped by more than 42% [2] Legal Proceedings - The deadline for investors to seek the role of lead plaintiff in the class action is April 6, 2026 [1] - Any member of the putative class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [2]

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged securities fraud affecting investors between August 3, 2023, and December 26, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx made misleading statements regarding the efficacy of setrusumab, particularly that while it increases bone density, it does not correlate with a decrease in annualized fracture rates [1] - On December 29, 2025, Ultragenyx announced that its Phase III Orbit and Cosmic Studies did not achieve statistical significance in reducing annualized clinical fracture rates compared to placebo or bisphosphonates [1] - Following the announcement, Ultragenyx's stock price plummeted from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025, marking a decline of approximately 42.32% in just one day [1] Group 2: Investor Information - Investors who suffered losses during the relevant time frame have until April 6, 2026, to request to be appointed as lead plaintiff in the lawsuit [1] - Class members may be entitled to compensation without any out-of-pocket costs or fees [1] - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [1]